ArticlePharmacoEconomics2021
Valuation of SF-6Dv2 Health States in China Using Time Trade-off and Discrete-Choice Experiment with a Duration Dimension.
Article in PharmacoEconomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The Evolving Landscape of Discrete Choice Experiments in Health Economics: A Systematic Review.PharmacoEconomics · 2025Pooled it
- Discrete Choice Experiments in Health State Valuation: A Systematic Review of Progress and New Trends.Applied health economics and health policy · 2023Pooled it
- China Health Related Outcomes Measures (CHROME): Development of a New Generic Preference-Based Measure for the Chinese Population.PharmacoEconomics · 2022Pooled it
- Cost Utility Analysis of Internet-Based Cognitive Behavioral Therapy for Major Depressive Disorder: Randomized Controlled Trial.Journal of medical Internet research · 2025Trial
- Health state values in cancer patients and the general population: evidence from SF-6Dv2.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Older Men's Preferences for HIV Testing in Primary Care Setting: Evidence from a Best-Worst Scaling Study in China.The patient · 2026Article
- A head-to-head comparison of health utilities and measurement properties of the EQ-5D-5L and SF-6Dv2 among people living with HIV in China.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Deriving a Korean SF-6Dv2 Value Set Using a Discrete Choice Experiment with Duration.PharmacoEconomics · 2026Article
- Assessing the health utility values of patients with six common cancers in China using the QLU-C10D: A cross-sectional survey.iScience · 2026Article
- Are there differences in health state preferences between urban and rural respondents? a comparison using time trade-off and discrete choice experiment.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Quality of life utility-Core 10 dimensions (QLU-C10D) scores based on cancer patients' health preferences are more sensitive than those based on general public's health preferences.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Cancer-specific or generic preference-based measures in oncology? A validity comparison across six commonly diagnosed cancers.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Testing culturally relevant EQ-5D-5L bolt-ons for the Chinese general population: first quantitative phase of a mixed methods study.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Mapping Health State Utility from Disease-Specific Measures in Spinal Muscular Atrophy and Paroxysmal Nocturnal Hemoglobinuria.PharmacoEconomics · 2026Article
- Assessment of health-related quality of life of patients with gout and hyperuricemia in the Tianjin area according to the SF-6Dv2 scale.Frontiers in public health · 2026Article
- Treatment patterns, access, and multidimensional burden of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in China: A nationwide cross-sectional study.Therapeutic advances in neurological disorders · 2026Article
- Health Utility Decrement of Injection Treatment-Related Attributes Using Time Trade-Off Among Type 2 Diabetes Patients: A Vignette-Based Study.PharmacoEconomics - open · 2026Article
- Comparison of the measurement properties of the EQ-5D-5L and SF-6Dv2 among patients with diabetes in China.Health and quality of life outcomes · 2025Article
- Minimal clinically important difference of EQ-5D-5L, SF-6Dv2, and QLU-C10D in hematologic malignancy patients in China.Health and quality of life outcomes · 2025Article
- Optimizing presentation formats for SF-6Dv2 health status valuation: a qualitative study using cognitive interviews.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesOur objective was to generate a value set for the SF-6Dv2 using time trade-off (TTO) and a discrete-choice experiment with a duration dimension (DCE
methodsA large representative sample of the Chinese general population was recruited from eight provinces/municipalities in China, stratified by age, sex, education level, and proportion of urban/rural residence. Respondents completed eight TTO tasks and ten DCE
resultsIn total, 3320 respondents (50.3% male; range 18-90 years) were recruited. The random-effects model and the conditional logit model were preferred for the TTO and DCE
conclusionsThe Chinese value set for the SF-6Dv2 was established based on the TTO approach, but the DCE
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.